In Reply

Arch Pathol Lab Med. 2019 Apr;143(4):413-414. doi: 10.5858/arpa.2018-0906-LE. Epub 2019 Jan 3.

Authors

Antonio C Wolff¹, M Elizabeth Hale Hammond², Kimberly H Allison³, Brittany E Harvey⁴, Lisa M McShane⁵, Mitchell Dowsett⁶

Affiliations

¹ 1 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
² 2 Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, Utah.
³ 3 Stanford University School of Medicine, Stanford, California.
⁴ 4 American Society of Clinical Oncology, Alexandria, Virginia.
⁵ 5 National Cancer Institute, Bethesda, Maryland.
⁶ 6 The Royal Marsden NHS Foundation Trust, London, United Kingdom.

PMID: 30605367
DOI: 10.5858/arpa.2018-0906-LE

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Humans
Medical Oncology
Pathologists
Receptor, ErbB-2
United States

Substances

ERBB2 protein, human
Receptor, ErbB-2